Clinical trials: Severe Emphysema
Heterogeneous Emphysema
Endoscopic Lung Volume Reduction After Catheter-based CV Measurement in Patients With Heterogeneous Emphysema and Complete Interlobar Fissures
This clinical trial evaluates the impact of catheter-based measurement of interloabr collateral ventilation prior to endoscopic lung volume reduction in patients with hetereogeneous emphysema and complete interlobar fissures in…
- Trial name
- NCT01902732
- Testing
- Implantation of valves (IBV)
- Where
- 5 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Heidelberg University
COPD
Trial Evaluating the Rate of Pneumothorax in Severe Emphysema Secondary to Endoscopic Volume Reduction With Two-stage ZEPHYR® Valves Versus Endoscopic Volume Reduction With One-stage ZEPHYR® Valves
Chronic obstructive pulmonary disease (COPD) affects 3.5 million people and is the third leading cause of death worldwide. Emphysema involves air retention in the lungs and is ultimately responsible for a major deterioration in…
- Trial name
- REPEAT (NCT06181357)
- Testing
- Endoscopic lung volume reduction in 2 stages, Endoscopic lung volume reduction in 1 stage
- Where
- 17 sites in France
- Volunteers
- 244 people
- Sponsor
- University Hospital, Limoges
Pulmonary Emphysema
Implantation of Endobronchial Valves Versus Intrabronchial Valves in Patients With Severe Heterogeneous Emphysema
Patients with advanced heterogeneous emphysema experience improvement in clinical outcomes in the same way following either implantation of endobronchial valves or intrabronchial valves.
- Trial name
- NCT01457833
- Testing
- EBV implantation, IBV implantation
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Heidelberg University
Empyhsema, Pulmonary Disease, Chronic Obstructive
The Spiration Valve System for the Treatment of Severe Emphysema
This is a multicenter, prospective, randomized, controlled study being conducted in China to evaluate improvement of lung function after treatment with the Spiration Valve System as compared to medical management in the control…
- Trial name
- REACH (NCT01989182)
- Testing
- Spiration Valve System, Medical Management
- Where
- 12 sites in China
- Volunteers
- 107 people
- Sponsor
- Olympus Corporation of the Americas
Emphysema or Chronic Obstructive Pulmonary Disease
BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation
Prospective, 2-arm, randomised (2:1), multicentre, open-label clinical trial in patients with severe emphysema. The intervention arm will be treated with Bronchoscopic lung volume reduction in severe emphysema using…
- Trial name
- NCT05717192
- Testing
- InterVapor®-System
- Where
- 12 sites in Germany
- Volunteers
- 224 people
- Sponsor
- IHF GmbH - Institut für Herzinfarktforschung
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)
The purpose of this study is to assess the efficacy (effectiveness) and safety of aclidinium bromide doses as compared to placebo in the treatment of moderate to severe chronic obstructive pulmonary disease.
- Trial name
- NCT00891462
- Testing
- Aclidinium bromide
- Where
- 112 sites in United States, Canada
- Volunteers
- 561 people
- Sponsor
- AstraZeneca
Emphysema
STRIVE Post-Market Registry Study
This is a single-arm, prospective, multi-center, Registry study to evaluate the long-term safety and effectiveness of the Spiration Valve System (SVS) for the treatment of severe emphysema in a post-market setting.
- Trial name
- NCT04302272
- Testing
- Spiration Valve System (SVS)
- Where
- 16 sites in United States
- Volunteers
- 150 people
- Sponsor
- Olympus Corporation of the Americas
Alpha-1 Antitrypsin Deficiency (AATD)
A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)
A Study of CTX460 in Adults with Emphysema Associated with Severe Alpha-1 Antitrypsin Deficiency (AATD).
- Trial name
- NCT07850076
- Testing
- CTX460
- Volunteers
- 68 people
- Sponsor
- CRISPR Therapeutics
Emphysema
A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema
This is a multicenter,single-arm,open-label study designed to evaluate improvement of lung function and safety after treatment with OL-BF-001 for severe emphysema.
- Trial name
- NCT02470052
- Testing
- OL-BF-001
- Where
- 10 sites in Japan
- Volunteers
- 38 people
- Sponsor
- Olympus Corporation
Emphysema or COPD
Chartis Collateral Ventilation Measurement: Conscious Sedation Versus General Anesthesia
Rationale: The Chartis® ( Pulmonx, CA, USA) measurement system is a tool to assess interlobar collateral ventilation during bronchoscopy.
- Trial name
- NCT03205826
- Testing
- Type of sedation used
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- University Medical Center Groningen
Alpha 1-Antitrypsin Deficiency
Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"
The goal of this clinical trial is to learn if AAT for inhalation, at a dose of 80 mg/day can slow the progression of lung disease in people who have lung disease caused by severe genetic deficiency in Alpha 1 Antitrypsin (AATD).
- Trial name
- InnovAATe (NCT04204252)
- Testing
- Alpha 1-Antitrypsin
- Where
- 9 sites in Belgium, Finland and 4 more
- Volunteers
- 98 people
- Sponsor
- Kamada, Ltd.
Chronic Obstructive Pulmonary Disease
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.
- Trial name
- NCT06981078
- Testing
- Verekitug
- Where
- 242 sites in United States, Argentina and 21 more
- Volunteers
- 666 people
- Sponsor
- Upstream Bio Inc.
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to assess the maintenance bronchodilator effects of the fixed dose combination versus monotherapies.
- Trial name
- NCT01437397
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate
- Where
- 222 sites in United States, Australia and 2 more
- Volunteers
- 1,692 people
- Sponsor
- AstraZeneca
Bullous Emphysema
Bronchoscopic Intrabullous Autologous Blood Instillation (BIABI) for Emphysema
Patients with large bullae (large empty air sacs in the lung) may benefit from bullectomy (surgery to resect these bullae), however this is a major surgery with significant potential morbidity and long hospital stays.
- Trial name
- BIABI (NCT01727037)
- Testing
- Bronchoscopic intrabullous autologous blood instillation
- Where
- 3 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to evaluate the long-term safety and tolerability of two fixed-dose combinations of inhaled aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo in…
- Trial name
- NCT01572792
- Testing
- Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate
- Where
- 208 sites in United States, Australia and 2 more
- Volunteers
- 921 people
- Sponsor
- AstraZeneca
Emphysema or COPD
First in Human Study to Assess an Implant to Treat Severe Emphysema
The goal of this clinical trial is to test the feasibility of an implant for severe emphysema in up to 30 participants. The main questions it aims to answer are: Is it safe? Does it work? Participants who meet eligibility…
- Trial name
- BREATHE-1 (NCT05854550)
- Testing
- Apreo Implant Group
- Where
- 2 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Apreo Health, Inc.
Chronic Obstructive Pulmonary Disease, Emphysema
LVR in Severe Emphysema Using Bronchoscopic Autologous Blood Instillation in Combination With Intra-bronchial Valves
A single arm pilot study of lung volume reduction in severe emphysema using bronchoscopic autologous blood instillation in combination with intra-bronchial valves.
- Trial name
- BLOOD-VALVES (NCT03010449)
- Testing
- Intra-bronchial valve and blood
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Chronic Obstructive Pulmonary Disease
Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this study is to assess the long-term safety and tolerability of inhaled aclidinium bromide/formoterol in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01437540
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Formoterol Fumarate
- Where
- 137 sites in United States
- Volunteers
- 590 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase II study is to evaluate the pharmacokinetics, safety, and tolerability of aclidinium/formoterol fixed dose combination (FDC 400/12 μg via the Almirall Inhaler and formoterol 12 μg via the Foradil®…
- Trial name
- NCT01551888
- Testing
- Aclidinium/formoterol 400/12μg, Formoterol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Emphysema
A Trial on the Effects of Bronchoscopic Lung Volume Reduction in Severe Emphysema.
Rationale: The published clinical trials investigating the bronchoscopic lung volume reduction, showing important patient-related improvements in efficacy, led to the acknowledgement of the treatment in the GOLD-COPD2017…
- Trial name
- SOLVE (NCT03474471)
- Testing
- Pulmonary rehabilitation, EBV treatment
- Where
- 2 sites in Netherlands
- Volunteers
- 96 people
- Sponsor
- University Medical Center Groningen